A carregar...
Tumefactive multiple sclerosis lesions in two patients after cessation of fingolimod treatment
BACKGROUND: Fingolimod (FTY) is the first oral medication approved for multiple sclerosis therapy. Until now, little has been known about the effects of FTY withdrawal regarding disease activity and development of tumefactive demyelinating lesions (TDLs), as already described in patients who discont...
Na minha lista:
| Publicado no: | Ther Adv Neurol Disord |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4622113/ https://ncbi.nlm.nih.gov/pubmed/26557898 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756285615594575 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|